GS-2426 for Solid Tumors

This trial explores the safety and tolerability of a drug called GS-2426 for individuals with advanced solid tumors lacking the enzyme MTAP. The primary goal is to assess the safety of GS-2426 and determine the optimal dose for future studies. Participants will receive the drug until their disease progresses or for up to 105 weeks. Suitable candidates have advanced solid tumors unresponsive to standard treatments and tumors missing the MTAP enzyme. As a Phase 1 trial, this research aims to understand how GS-2426 works in people, offering participants the opportunity to be among the first to receive this new treatment.

Research shows that GS-2426 is in early testing for individuals with advanced solid tumors lacking the enzyme MTAP. This Phase 1 trial primarily tests the drug's safety and determines the appropriate dose. Consequently, there is limited information on how well participants can tolerate GS-2426.

GS-2426 is unique because it targets solid tumors with a novel approach that distinguishes it from traditional chemotherapy and immunotherapy treatments. Unlike existing options that often rely on broadly attacking cancer cells, GS-2426 may offer a more precise mechanism of action, potentially leading to fewer side effects and better targeting of tumor cells. Researchers are excited because this specificity might not only improve treatment effectiveness but also enhance patient quality of life by minimizing damage to healthy cells.

Research has shown that GS-2426 is being tested in individuals with advanced solid tumors that have a specific genetic change called MTAP deletion. This genetic change, common in several cancer types, can accelerate tumor growth. GS-2426 targets a pathway that these cancer cells rely on due to the MTAP deletion. Early lab studies have indicated it might slow the growth of these cancer cells. In this trial, participants will receive GS-2426 monotherapy in two phases: a dose escalation phase and a dose expansion phase. Researchers aim to assess its safety and effectiveness in humans, as studies in this area remain limited.⁶⁷⁸⁹¹⁰